<DOC>
	<DOCNO>NCT02971696</DOCNO>
	<brief_summary>The aim study evaluate efficacy sorafenib , compare best supportive care ( BSC ) , two cohort patient present advanced hepatocellular carcinoma ( HCC ) base etiology hepatitis C virus .</brief_summary>
	<brief_title>Sorafenib Versus Best Supportive Care Egyptian Hepatocellular Carcinoma Patients .</brief_title>
	<detailed_description>In Egypt , chronic hepatitis C virus ( HCV ) infection occur around 10 % population ( 8 million individual ) , lead cause liver cirrhosis , hepatocellular carcinoma , mortality . Although HCV genotype 4 constitutes 20 % HCV infection worldwide , prevalence Egypt 90 % . ( Waked et al. , 2016 ) In 2014 Omar et al . review 41 patient study evaluate Sorafenib Egyptian patient advance hepatocellular carcinoma median follow period 13 month , median PFS whole group 4 month ; median OS whole group 6.25 month . ( Abdel-Rahman et al. , 2014 ) Till current , study evaluate Sorafenib efficacy comparison best supportive care treatment HCC patient whose etiology HCV genotype 4 ( prevalent hepatitis C virus genotype Egypt ) . So , The study aim evaluate efficacy sorafenib , compare best supportive care ( BSC ) , two cohort patient present advanced hepatocellular carcinoma ( HCC ) base etiology hepatitis C virus .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients ≥18 year age 2 . Patients base etiology hepatitis C virus . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less 4 . ChildPugh liver function class A 5 . A life expectancy 12 week 6. adequate hematologic function ( platelet count , ≥60×109 per liter ; hemoglobin , ≥8.5 g per deciliter ; prothrombin time international normalized ratio , ≤2.3 ; prothrombin time , ≤6 second control ) , adequate hepatic function ( albumin , ≥2.8 g per deciliter ; total bilirubin , ≤3 mg per deciliter [ 51.3 µmol per liter ] ; alanine aminotransferase aspartate aminotransferase , ≤5 time upper limit normal range ) , adequate renal function ( serum creatinine , ≤1.5 time upper limit normal range ) . 7 . Patients require least one untreated target lesion could measure one dimension , accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1 . Had previously receive molecularly target therapy systemic treatment . 2 . Any co morbid disease confuse assessment QLQ30 score .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>